

# Microvascular lesions in the brain: a new perspective on cognitive impairment in type 2 diabetes

Published: 26-05-2009

Last updated: 05-05-2024

Primary Objective: 1) To characterize microbleeds and microinfarcts at 7T, and compare their prevalence in people with and without diabetes, with or without cognitive impairment  
Secondary Objective(s): 2) To assess the relevance of the lesions in the...

<b>Ethical review</b>	Not approved
<b>Status</b>	Will not start
<b>Health condition type</b>	Diabetic complications
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON33312

### Source

ToetsingOnline

### Brief title

Cerebral microvascular lesions in type 2 diabetes

### Condition

- Diabetic complications
- Encephalopathies
- Vascular haemorrhagic disorders

### Synonym

type 2 diabetes mellitus

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Universitair Medisch Centrum Utrecht

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** brain imaging, cognition, microvascular lesions, Type 2 diabetes

## Outcome measures

### Primary outcome

The prevalence and total number of microinfarcts and microbleeds at 7T in relation to DM2 status and cognition.

### Secondary outcome

Microvascular lesion load will be related to cognition, conventional MR markers (atrophy, white matter hyperintensities), vascular and metabolic risk factors, brain connectivity parameters and cerebral blood flow.

## Study description

### Background summary

Type 2 diabetes (DM2) is associated with cognitive decrements and an increased risk of dementia. Further insight in the natural history and etiology of these decrements is required to optimize treatment. We aim to identify novel brain imaging correlates of impaired cognition in DM2, which may serve as a surrogate outcome measure in future intervention studies.

Neuropathological studies identify microvascular lesions, i.e. microinfarcts and microbleeds, as important correlates of impaired cognition in older individuals, but these lesions go largely undetected on conventional MR imaging. The introduction of high field strength clinical MR scanners now enables the detection these lesions in vivo. Our hypotheses are that

- microvascular lesions are more common in patients with DM2 and can be detected with high resolution magnetic MR imaging at high field strength (7 Tesla)

- a higher lesion load is associated with impaired cognition, both in older individuals with and without DM2

### Study objective

### Primary Objective:

1) To characterize microbleeds and microinfarcts at 7T, and compare their prevalence in people with and without diabetes, with or without cognitive impairment

### Secondary Objective(s):

2) To assess the relevance of the lesions in the context of DM2:

- The occurrence of microbleeds and microinfarcts at 7T will be related to other imaging markers of DM2, including WMH volume and diffusion tensor imaging (DTI).
- The occurrence of microbleeds and microinfarcts at 7T will be related to cerebral perfusion and to the presence of metabolic and vascular risk factors

3) To assess the relevance of the lesions in older individuals without DM2

## Study design

This is an observational cross-sectional population-based study

## Study burden and risks

Approximately 600 eligible individuals will undergo a short telephone interview including a cognitive screening test (10 min). Based on the interview 140 individuals will be visited at home for a detailed neuropsychological assessment (1 hour). From this group, 112 will be selected for a visit to the UMC Utrecht. The visit includes a medical examination (30 min) in which blood is drawn (3x5ml), a 1.5Tesla and 7Tesla MRI scan of 30 minutes each and photograph of the retina. There are no health risks associated with the procedures and techniques used.

## Contacts

### Public

Universitair Medisch Centrum Utrecht

Heidelberglaan 100, postbus 85500  
3508 GA Utrecht  
Nederland

### Scientific

Universitair Medisch Centrum Utrecht

Heidelberglaan 100, postbus 85500  
3508 GA Utrecht  
Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

age between 65 and 80 years

diabetes patients: diagnosed with diabetes for more than 1 year

### Exclusion criteria

- Dementia
- TIA or non-invalidating stroke in the past 2 years or any invalidating stroke.
- Other neurological diseases, unrelated to DM2, that are likely to affect cognition, including a history of brain trauma requiring hospitalisation
- Known with or history of psychiatric disorders requiring hospitalisation or >12 months medication use (e.g. schizophrenia , Major depression (DSM IV))
- Contra-indication for 7 Tesla MR imaging (as established by the department)

## Study design

### Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active

Primary purpose: Basic science

## Recruitment

NL  
Recruitment status: Will not start  
Enrollment: 140  
Type: Anticipated

## Ethics review

Not approved  
Date: 26-05-2009  
Application type: First submission  
Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
CCMO	NL27076.041.09